Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity

Journal of Medicinal Chemistry

Volumn 52, Issue 12, 2009, Pages 3742-3752

  Hicks, Latorya D ^a   Hyatt, Janice L ^c   Stoddard, Shana ^b   Tsurkan, Lyudmila ^a   Edwards, Carol C ^a   Wadkins, Randy M ^b   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO N (4 ETHOXYPHENYL)BENZENESULFONAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BENZENE DERIVATIVE; CARBOXYLESTERASE; ENZYME INHIBITOR; FLUORENE DERIVATIVE; HUMAN INTESTINAL CARBOXYLESTERASE; HUMAN INTESTINAL CARBOXYLESTERASE INHIBITOR; IRINOTECAN; N,N' (1,4 PHENYLENE)BIS(4 CHLOROBENZENESULFONAMIDE); N,N' [1,4' DISULFANEDIYLBIS(4,1 PHENYLENE)]DIMETHANESULFONAMIDE; PRODRUG; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; DIARRHEA; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROLYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INTESTINES; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 67549128953     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9001296     Document Type: Article

References (44)

1. Cashman, J.; Perroti, B.; Berkman, C.; Lin, J. Pharmacokinetics and molecular detoxification. Environ. Health Perspect. 1996, 104, 23-40.
2. Kunimoto, T.; Nitta, K.; Tanaka, T.; Uehara, N.; Baba, H.; Takeuchi, M.; Yokokura, T.; Sawada, S.; Miyasaka, T.; Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987, 47, 5944-5947. (Pubitemid 18018734)
3. Pindel, E. V.; Kedishvili, N. Y.; Abraham, T. L.; Brzezinski, M. R.; Zhang, J.; Dean, R. A.; Bosron, W. F. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem. 1997, 272, 14769-14775.
4. Bencharit, S.; Morton, C. L.; Xue, Y.; Potter, P. M.; Redinbo, M. R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 2003, 10, 349-356.
5. Kamendulis, L. M.; Brzezinski, M. R.; Pindel, E. V.; Bosron, W. F.; Dean, R. A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther. 1996, 279, 713-717.
6. Brzezinski, M. R.; Spink, B. J.; Dean, R. A.; Berkman, C. E.; Cashman, J. R.; Bosron, W. F. Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab. Dispos. 1997, 25, 1089-1096
7. Shi, D.; Yang, J.; Yang, D.; LeCluyse, E. L.; Black, C.; You, L.; Akhlaghi, F.; Yan, B. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 2006, 319, 1477-1484
8. Zhang, J.; Burnell, J. C.; Dumaual, N.; Bosron, W. F. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J. Pharmacol. Exp. Ther. 1999, 290, 314-318.
9. Alexson, S. E.; Diczfalusy, M.; Halldin, M.; Swedmark, S. Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine. Drug Metab. Dispos. 2002, 30, 643-647.
10. Tsuji, T.; Kaneda, N.; Kado, K.; Yokokura, T.; Yoshimoto, T.; Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobiodynamics 1991, 14, 341-349.
11. Potter, P. M.; Pawlik, C. A.; Morton, C. L.; Naeve, C. W.; Danks, M. K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug Irinotecan (CPT-11). Cancer Res. 1998, 52, 2646-2651. (Pubitemid 28275439)
12. Humerickhouse, R.; Lohrbach, K.; Li, L.; Bosron, W.; Dolan, M. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000, 60, 1189-1192. (Pubitemid 30151980)
13. Khanna, R.; Morton, C. L.; Danks, M. K.; Potter, P. M. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res. 2000, 60, 4725-4728.
14. Wierdl, M.; Tsurkan, L.; Hyatt, J. L.; Hatfield, M. J.; Edwards, C. C.; Danks, M. K.; Redinbo, M. R.; Potter, P. M. An improved human carboxylesterase for use in enzyme/prodrug therapy with CPT-11. Cancer Gene Ther. 2008, 15, 183-192. (Pubitemid 351240667)
15. Tabata, T.; Katoh, M.; Tokudome, S.; Nakajima, M.; Yokoi, T. Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab. Dispos. 2004, 32, 1103-1110.
16. Quinney, S. K.; Sanghani, S. P.; Davis, W. I.; Hurley, T. D.; Sun, Z.; Murry, D. J.; Bosron, W. F. Hydrolysis of capecitabine to 5′-deoxy-5- fluorocytidine by human carboxylesterases and inhibition by loperamide. J. Pharmacol. Exp. Ther. 2005, 313, 1011-1016.
17. Stampfli, H. F.; Quon, C. Y. Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res. Commun. Mol. Pathol. Pharmacol. 1995, 88, 87-97.
18. Morton, C. L.; Iacono, L.; Hyatt, J. L.; Taylor, K. R.; Cheshire, P. J.; Houghton, P. J.; Danks, M. K.; Stewart, C. F.; Potter, P. M. Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol. 2005, 56, 629-636.
19. Beroza, P.; Damodaran, K.; Lum, R. T. Target-related affinity profiling: Telik's lead discovery technology. Curr. Top. Med. Chem. 2005, 5, 371-381.
20. Wadkins, R. M.; Hyatt, J. L.; Wei, X.; Yoon, K. J.; Wierdl, M.; Edwards, C. C.; Morton, C. L.; Obenauer, J. C.; Damodaran, K.; Beroza, P.; Danks, M. K.; Potter, P. M. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J. Med. Chem. 2005, 48, 2905-2915.
21. Wadkins, R. M.; Hyatt, J. L.; Yoon, K. J.; Morton, C. L.; Lee, R. E.; Damodaran, K.; Beroza, P.; Danks, M. K.; Potter, P. M. Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol. Pharmacol. 2004, 65, 1336-1343.
22. Bencharit, S.; Morton, C. L.; Hyatt, J. L.; Kuhn, P.; Danks, M. K.; Potter, P. M.; Redinbo, M. R. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine. From binding promiscuity to selective inhibition. Chem. Biol. 2003, 10, 341-349.
23. Webb, J. L. Enzyme and Metabolic Inhibitors, Volume 1. General Principles of Inhibition; Academic Press Inc.: New York, 1963.
24. Hyatt, J. L.; Moak, T.; Hatfield, J. M.; Tsurkan, L.; Edwards, C. C.; Wierdl, M.; Danks, M. K.; Wadkins, R. M.; Potter, P. M. Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J. Med. Chem. 2007, 50, 1876-1885.
25. Potter, P. M.; Wadkins, R. M. Carboxylesterases-detoxifying enzymes and targets for drug therapy. Curr. Med. Chem. 2006, 13, 1045-1054.
26. Lundstedt, T.; Seifert, E.; Abramo, L.; Thelin, B.; Nystrom, A.; Pettersen, J.; Bergman, B. Experimental design and optimization. Chemom. Intell. Lab. Syst. 1998, 42, 3-40.
27. Hicks, L. D.; Hyatt, J. L.; Moak, T.; Edwards, C. C.; Tsurkan, L.; Wierdl, M.; Ferreira, A. M.; Wadkins, R. M.; Potter, P. M. Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg. Med. Chem. 2007, 15, 3801-3817.
28. Hyatt, J. L.; Stacy, V.; Wadkins, R. M.; Yoon, K. J.; Wierdl, M.; Edwards, C. C.; Zeller, M.; Hunter, A. D.; Danks, M. K.; Crundwell, G.; Potter, P. M. Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. J. Med. Chem. 2005, 48, 5543-5550.
29. Wadkins, R. M.; Hyatt, J. L.; Edwards, C. C.; Tsurkan, L.; Redinbo, M. R.; Wheelock, C. E.; Jones, P. D.; Hammock, B. D.; Potter, P. M. Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol. Pharmacol. 2007, 71, 713-723.
30. Wadkins, R. M.; Morton, C. L.; Weeks, J. K.; Oliver, L.; Wierdl, M.; Danks, M. K.; Potter, P. M. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol. Pharmacol. 2001, 60, 355-362.
31. Brandstetter, H.; Turk, D.; Hoeffken, H. W.; Grosse, D.; Sturzebecher, J.; Martin, P. D.; Edwards, B. F.; Bode, W. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J. Mol. Biol. 1992, 226, 1085-1099.
32. Sturzebecher, J.; Hauptmann, J.; Steinmetzer, T., Thrombin. In Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development; Smith, H. J.; Simmons, C., Eds.; Taylor & Francis: London, 2002; pp 185-201.
33. Okamoto, S.; Kinjo, K.; Hijikata, A.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tonomura, S. Thrombin inhibitors. 1. Ester derivatives of N-alpha-(arylsulfonyl)-L-arginine. J. Med. Chem. 1980, 23, 827-830.
34. Sturzebecher, J.; Markwardt, F.; Voigt, B.; Wagner, G.; Walsmann, P. Cyclic amides of N-alpha-arylsulfonylaminoacylated 4-amidinophenylalanine-tight binding inhibitors of thrombin. Thromb. Res. 1983, 29, 635-642.
35. Morton, C. L.; Potter, P. M. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda and COS7 cells for recombinant gene expression: application to a rabbit liver carboxylesterase. Mol. Biotechnol. 2000, 16, 193-202.
36. Hyatt, J. L.; Wadkins, R. M.; Tsurkan, L.; Hicks, L. D.; Hatfield, M. J.; Edwards, C. C.; Ii, C. R.; Cantalupo, S. A.; Crundwell, G.; Danks, M. K.; Guy, R. K.; Potter, P. M. Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J. Med. Chem. 2007, 50, 5727-5734.
37. Guichard, S.; Morton, C. L.; Krull, E. J.; Stewart, C. F.; Danks, M. K.; Potter, P. M. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin. Cancer Res. 1998, 4, 3089-3094.
38. Stewart, J. J. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
39. Vedani, A.; Dobler, M. Multidimensional QSAR: moving from three- to five-dimensional concepts. Quant. Struct.-Act. Relat. 2002, 21, 382-390.
40. Vedani, A.; Dobler, M. 5D-QSAR: the key for simulating induced fit. J. Med. Chem. 2002, 45, 2139-2149.
41. Vedani, A.; Dobler, M.; Lill, M. A. Combining protein modeling and 6D-QSAR simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005, 48, 3700-3703.
42. Hawkins, G. D.; Giesen, D.; Lynch, G.; Chambers, C.; Rossi, I.; Storer, J.; Li, J.; Zhu, T.; Thompson, J.; Winget, P.; Lynch, B.; Rinaldi, D.; Liotard, D.; Cramer, C. J.; Truhlar, D. G., V. Amsol, version 7.1; University of Minnesota: Minneapolis, 2004.
43. Merritt, E. A.; Bacon, D. J. Raster 3D: Photorealistic molecular graphics. Methods Enzymol. 1997, 277, 505-524.
44. Kraulis, P. J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 1991, 24, 946-950.